Bristol-myers Squibb

This study is testing whether a daily pill called deucravacitinib can safely reduce disease activity in people with moderate to severe systemic lupus erythematosus (SLE). It will compare the pill to a placebo in 516 participants who are already taking standard lupus medications. …

This study is testing if adding an immunotherapy drug (nivolumab) to standard chemotherapy, both before and after surgery, is better at preventing cancer from returning in people with early-stage, operable lung cancer. About 461 participants with stage II or III non-small cell lu…

This study is testing a drug called fedratinib in Japanese adults with a serious bone marrow cancer called myelofibrosis. The goal is to find a safe and effective dose that can reduce spleen size and ease symptoms like fatigue and abdominal discomfort. Participants will take the …

This study is comparing two drugs, repotrectinib and crizotinib, for people with advanced non-small cell lung cancer that has a specific genetic marker called ROS1. The main goal is to see which drug is better at delaying cancer growth and is safer for patients. It is for people …

This study is testing whether a pill called oral azacitidine can help control a type of early-stage blood cancer called myelodysplastic syndrome (MDS). About 230 people with low or intermediate-risk MDS will take either the pill or a placebo, along with standard supportive care. …

This study is testing an oral medication called deucravacitinib to see if it safely reduces joint pain, swelling, and skin symptoms in people with active psoriatic arthritis. It involves about 670 participants who have not yet tried advanced biologic drugs. The main goal is to se…

This study is monitoring the long-term safety of abatacept, a medication used to control juvenile idiopathic arthritis. Researchers are tracking 800 children and teens already taking this drug to see how often serious infections, cancers, or other autoimmune conditions occur. The…

This study follows people with moderate-to-severe plaque psoriasis who continue taking the drug deucravacitinib long-term to monitor its ongoing safety and effectiveness. It also includes a smaller group to see if the drug affects how well vaccines for pneumonia and tetanus work.…

This study is testing whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) works better than just one of them (nivolumab alone) for people with advanced kidney cancer that has spread. It involves 437 adults with newly diagnosed, aggressive forms of the dise…

This study is testing a new drug called BMS-986158 for people with intermediate or high-risk myelofibrosis, a serious blood cancer. Researchers want to see if the drug is safe and works better when given alone or combined with two other approved myelofibrosis medications. The tri…

This large, late-stage trial is comparing two immunotherapy approaches against standard chemotherapy for people with advanced colorectal cancer that has spread and has specific genetic features (MSI-H/dMMR). The study aims to see if the immunotherapy drugs nivolumab alone or comb…

This study is testing if a new under-the-skin injection of the cancer drug nivolumab works as well as the standard intravenous (IV) version for people with advanced kidney cancer that has spread or returned after prior treatment. It involves about 681 participants and aims to see…

This study is testing the effectiveness and safety of giving the highest approved dose of the drug luspatercept to people with a lower-risk form of myelodysplastic syndromes (MDS) who need regular red blood cell transfusions. The main goal is to see if the treatment can help pati…

This study is testing whether a new two-drug combination (relatlimab plus nivolumab) is more effective at controlling advanced melanoma than the standard single drug (nivolumab). It involves over 700 adults with previously untreated melanoma that has spread or cannot be surgicall…

This study is observing how well a medication called deucravacitinib works for adults with moderate-to-severe plaque psoriasis in everyday German clinics over five years. It will follow 550 patients who have already been prescribed the drug by their doctor to see how much their s…

This study is testing if adding a new drug called relatlimab to a standard treatment (nivolumab plus chemotherapy) works better for people with advanced or recurrent non-small cell lung cancer. It will involve about 468 adults who have not yet received treatment for their advance…

This study is testing whether an oral medication called deucravacitinib is safe and effective at reducing skin inflammation in people with discoid or subacute cutaneous lupus. About 74 participants with moderate to severe skin symptoms that aren't well controlled by standard trea…

This study observes how long people with relapsing-remitting multiple sclerosis (MS) continue taking a medication called ozanimod in everyday clinic settings. It involves 200 patients in Spain who are new to MS treatment and have low-to-moderate disease activity. The main goal is…

This study is testing whether the drug nivolumab can help prevent liver cancer from returning in people who are at high risk of recurrence after their initial tumor has been completely removed by surgery or destroyed by ablation. It compares nivolumab against a placebo in about 5…

This large, late-stage trial is comparing a new two-drug immunotherapy combination (nivolumab plus ipilimumab) against the current standard drug treatments (sorafenib or lenvatinib) for people with advanced liver cancer who haven't had prior drug therapy. The main goal is to see …

This study tested whether a drug called nivolumab could help prevent invasive bladder cancer from returning after surgery. It involved 709 patients who had their cancer surgically removed but were at high risk of it coming back. Participants received either the drug or a placebo …

This study is testing a drug called luspatercept to see if it is safe and effective for treating anemia in people with two specific blood disorders: myelodysplastic syndromes (MDS) or beta-thalassemia. The goal is to help patients who currently need regular red blood cell transfu…

This early-stage study is testing an experimental drug called BMS-986488, both alone and in combination with other therapies, in people with advanced cancers that have spread or cannot be removed by surgery. The main goals are to check if the treatment is safe and tolerable, and …

This study is testing whether adding an oral medication called azacitidine to standard supportive care can help keep acute myeloid leukemia (AML) from returning in Japanese patients aged 55 and older. Participants are in remission after initial chemotherapy. The goal is to see if…

This large Phase 3 study is testing whether the investigational drug BMS-986278 can safely slow the progression of idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. It involves about 1,255 adults with IPF who will receive either the drug or a placebo. Research…

This large, late-stage study is testing whether an oral medication called deucravacitinib can better control active, moderate-to-severe lupus compared to a placebo. It involves over 500 participants who will take the pill alongside their standard lupus treatments. The main goal i…

This study is testing whether adding a new drug called mezigdomide to a standard two-drug therapy works better for people with multiple myeloma that has returned or stopped responding to treatment. About 525 participants who have had at least one prior treatment, including specif…

This study is testing whether the medication mavacamten can help control symptoms and reduce strain on the heart in teenagers (ages 12-17) who have a genetic condition that causes the heart muscle to thicken and obstruct blood flow. It is a Phase 3 trial involving 44 participants…

This study allows a small group of lymphoma patients who have been successfully taking the experimental drug CC-122 for over five years in earlier trials to continue receiving it. The main goal is to monitor the long-term safety of the treatment for these specific patients. It is…

This study is testing whether adding a pill called oral azacitidine to standard care can help keep acute myeloid leukemia (AML) from coming back in Chinese patients who have achieved remission. It will compare the pill plus standard care against standard care alone. The main goal…

This large, late-stage study is testing whether an oral medication called deucravacitinib can safely reduce disease activity and improve symptoms for adults with active Sjögren's syndrome. About 774 participants will receive either the drug or a placebo for a year to see if it le…

This study is testing if the drug mavacamten can improve the physical structure of the heart in adults with a condition called obstructive hypertrophic cardiomyopathy (oHCM), where the heart muscle is abnormally thick. Researchers will use special heart MRI scans to measure chang…

This large, late-stage study is testing whether an investigational drug called BMS-986278 can slow the progression of pulmonary fibrosis, a serious condition that causes permanent lung scarring. It will involve over 1,000 participants and compare the drug's effects against a plac…

This study is looking at how well an oral medication called ONUREG (azacitidine) works in real-world settings to help keep acute myeloid leukemia (AML) from coming back. It involves 44 adults in Hong Kong who have achieved remission after initial chemotherapy but cannot or choose…

This study is testing whether adding an experimental drug called BMS-986012 to standard chemotherapy and immunotherapy works better for people newly diagnosed with extensive-stage small cell lung cancer. Researchers want to see if this combination is safe and can help patients li…

This large, late-stage study is testing whether adding immunotherapy drugs (nivolumab with or without BMS-986205) to standard chemotherapy before bladder removal surgery, and continuing them afterward, works better than chemotherapy alone. It involves 855 adults with muscle-invas…

This large, late-stage study is comparing new immunotherapy drug combinations against standard chemotherapy for people with advanced bladder cancer that has spread or cannot be removed by surgery. It enrolled over 1,300 patients who had not received prior treatment for their adva…

This study is looking back at the medical records of children in the Netherlands who were treated for advanced melanoma with a drug called ipilimumab. The goal is to understand the long-term side effects, survival rates, and overall health outcomes for these young patients. It is…

This study is collecting information from about 400 patients in Italy who are already receiving a specific two-drug immunotherapy combination (nivolumab plus ipilimumab) as their first treatment for advanced or returning non-small cell lung cancer. The goal is to understand how w…

This study looks back at medical records to understand the side effects and healthcare needs of 300 people with advanced lung cancer who have low levels of a specific protein (PD-L1). It examines patients who received various first-line immunotherapy treatments to see how common …

This study looks back at the medical records of about 1,300 adults in Spain with a specific, less-severe type of blood disorder that requires regular blood transfusions. The goal is to understand how common this condition is, what treatments doctors typically use first, and how p…

This study observes how approved multiple myeloma treatments work in everyday clinical practice, not in controlled trials. It follows over 2,500 patients who are already receiving standard treatments for either newly diagnosed or relapsed disease. Researchers track survival, trea…

This study aimed to measure how much ozanimod medication passes into breast milk when taken by nursing mothers. It planned to enroll women already using ozanimod who had recently given birth, to assess the drug's concentration in their milk and monitor their infants for any effec…